Physician profile
Sumy Anthony
NPI 1003240862
$6,428.55
in general payments reported to CMS, 2019-2025
32 companies · $912 in 2025
The $912 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,117 · 2023: $1,243 · 2024: $1,156 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,957 · Education: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,957.30 |
| Education | $353.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,061.10 | 2022-2024 | |
| Exelixis INC. | $626.14 | 2022-2025 | Cabometyx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $443.23 | 2022-2023 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $434.82 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $409.35 | 2022-2025 | Tecvayli, Stelara, Carvykti |
| Celgene Corporation | $362.32 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $273.36 | 2022-2024 | Libtayo, Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $240.65 | 2022-2023 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $216.62 | 2022-2023 | Zeposia |
| Tersera Therapeutics LLC | $141.86 | 2024-2025 | Zoladex |
| Merck Sharp & Dohme LLC | $127.72 | 2022-2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $120.89 | 2024 | Enhertu |
| Intercept Pharmaceuticals, INC. | $119.63 | 2022-2023 | Ocaliva |
| Eisai INC. | $115.75 | 2024-2025 | |
| Astellas Pharma US INC | $87.66 | 2024-2025 | Vyloy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $86.74 | 2022-2024 | Enhertu |
| Pfizer INC. | $71.26 | 2022-2023 | |
| Genmab U.S., INC. | $59.29 | 2025 | Tivdak |
| Genzyme Corporation | $56.61 | 2023 | |
| Organon LLC | $56.23 | 2022 | |
| Ferring Pharmaceuticals INC. | $55.12 | 2022-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $46.85 | 2022 | |
| Nestle Healthcare Nutrition INC. | $29.00 | 2022 | |
| Sobi, INC | $25.70 | 2025 | |
| Braintree Laboratories, INC. | $24.00 | 2022 | |
| Qol Medical, LLC | $21.17 | 2022 | |
| Ardelyx, INC. | $21.11 | 2023 | Ibsrela |
| Myriad Genetic Laboratories, INC. | $20.29 | 2025 | Myrisk |
| Fresenius Kabi USA, LLC | $20.13 | 2023 | Idacio |
| Bayer Healthcare Pharmaceuticals INC. | $19.18 | 2024 | |
| Amgen INC. | $18.63 | 2022 | |
| Redhill Biopharma INC. | $16.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumy Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.